Notably, JAK2-homozygous mutation carriers had significantly higher expression level of MAPK14 than that of all other mutation types MPN patients and normal donors (p < 0.05, Fig. 6B). This evidence concerns the gene JAK2 and myeloproliferative neoplasm.